# Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies

> **NCT02666248** · — · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 3 (actual)

## Conditions studied

- Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02666248
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2018-01-27
- **Final completion:** 2018-01-27
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02666248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02666248, "Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02666248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*